Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure.
Agata JędrzejewskaAlicja BraczkoAda KaweckaMarzena Romanowska-KocejkoPiotr SiondalskiEwa SlominskaBarbara Kutryb-ZajacMagdi H YacoubRyszard Tomasz SmolenskiPublished in: International journal of molecular sciences (2022)
LVAD therapy is an effective rescue in acute and especially chronic cardiac failure. In several scenarios, it provides a platform for regeneration and sustained myocardial recovery. While unloading seems to be a key element, pharmacotherapy may provide powerful tools to enhance effective cardiac regeneration. The synergy between LVAD support and medical agents may ensure satisfying outcomes on cardiomyocyte recovery followed by improved quality and quantity of patient life. This review summarizes the previous and contemporary strategies for combining LVAD with pharmacotherapy and proposes new therapeutic targets. Regulation of metabolic pathways, enhancing mitochondrial biogenesis and function, immunomodulating treatment, and stem-cell therapies represent therapeutic areas that require further experimental and clinical studies on their effectiveness in combination with mechanical unloading.
Keyphrases
- stem cells
- left ventricular
- heart failure
- smoking cessation
- left ventricular assist device
- liver failure
- climate change
- randomized controlled trial
- cell therapy
- drug induced
- healthcare
- cardiac resynchronization therapy
- systematic review
- oxidative stress
- replacement therapy
- respiratory failure
- high throughput
- angiotensin ii
- type diabetes
- metabolic syndrome
- atrial fibrillation
- adipose tissue
- hepatitis b virus
- combination therapy
- glycemic control
- high glucose